A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.
Advanced Breast Cancer|Other Solid Tumors
DRUG: Comparator: MK0752, Notch Inhibitor|DRUG: Comparator: MK0752, Notch Inhibitor - 450 mg|DRUG: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|DRUG: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|DRUG: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Safety and tolerability; MTD will be established, Day 1 to Day 28
Overall tumor/disease response will be evaluated using RECIST criteria, radiographic and clinical evaluations, radigraphic evaluation = every 56 days
An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.